In fact, there is a substantial cross-over between treatment strategies for CAD and HFrEF, such as the use of β-blockers and an angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, with addition of a mineralocorticoid receptor antagonist in patients with persistent symptoms (Chang et al., 2018). The gene discussed is NR3C2; the disease is coronary artery disorder.